SPG Springer Nature AG & Co. KGaA
Springer Nature AG & Co. KGaA, together with its subsidiaries, engages in the publishing business in Germany, the United Kingdom, the United States, and internationally. The company operates through three segments: Research, Education, and Health. It offers journals across various academic disciplines under the Nature Portfolio and Springer brand names; books in print and digital formats across various scientific disciplines, including monographs, textbooks, conference proceedings, handbook series, reference works, and briefs under the Springer and Palgrave Macmillan brand names; and support services to researchers, institutions, and industry professionals with AI-powered tools and services, such as AdisInsight, Springer Nature Experiments, protocols.io, and SpringerMaterials, as well as professional development and career services under the Nature Masterclasses, Nature Careers, and Nature Conferences brand names. The company also provides English language teaching content and national curricula learning resources under the Macmillan Education brand name. In addition, it offers specialist information and services to healthcare professionals under the Springer Medizin brand name; publications, learning solutions, and professional services to healthcare practitioners and students under the BSL brand name; content and services related to drug treatments, medical devices, and diagnostics under the Springer Health+ brand name; and Cureus Journal of Medical Science, a peer-reviewed OA medical journal. The company was founded in 1842 and is based in Berlin, Germany. Springer Nature AG & Co. KGaA operates as a subsidiary of GvH Vermögensverwaltungsgesellschaft Xxxiii mbH.…
Industry Peers
PublishingKey Statistics
About Springer Nature (ETR: SPG)
›
Springer Nature (ETR: SPG) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Publishing industry, part of the Communication Services sector, and reports about 9,400 employees.
The shares were at 22.45 EUR on 20 November 2026, up 10.3% over 52 weeks. Its 52-week range is 14.70 EUR to 23.55 EUR: the price is 4.7% below the high and 52.7% above the low.
At a market capitalisation of 4.47B EUR, it trades at 13.8 times trailing earnings and 12.1 times forward earnings. The median trailing P/E of its 17 largest Publishing peers is 16.9, a discount of 18% for SPG.
Springer Nature reports return on equity of 17.6%, an operating margin of 24.1% and revenue up 3.0% year over year.
Its debt exceeds its cash by 1.16B EUR, a debt-to-equity ratio of 0.74. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 27.00 EUR is 20.3% above the current price.